These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
237 related items for PubMed ID: 9413212
1. Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin. Hong WS, Jung HY, Yang SK, Kim HR, Min YI. Anticancer Res; 1997; 17(5A):3613-6. PubMed ID: 9413212 [Abstract] [Full Text] [Related]
2. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N. Cancer Res; 1989 Aug 01; 49(15):4098-102. PubMed ID: 2472873 [Abstract] [Full Text] [Related]
3. In vitro antitumor activity of 4'-O-tetrahydropyranyladriamycin on human gastric cancer cells. Yamaue H, Tanimura H, Noguchi K, Shono Y, Iwahashi M, Hotta T, Tani M, Tsunoda T, Nishimoto N, Terasawa H, Nakamori M. Anticancer Res; 1996 Aug 01; 16(1):243-6. PubMed ID: 8615614 [Abstract] [Full Text] [Related]
4. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines. Lee YS, Nishio K, Ogasawara H, Funayama Y, Ohira T, Saijo N. Cancer Res; 1995 Mar 01; 55(5):1075-9. PubMed ID: 7866991 [Abstract] [Full Text] [Related]
5. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Fukuda M, Ohe Y, Kanzawa F, Oka M, Hara K, Saijo N. Anticancer Res; 1995 Mar 01; 15(2):393-8. PubMed ID: 7763011 [Abstract] [Full Text] [Related]
6. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. Tsuruo T, Yusa K, Sudo Y, Takamori R, Sugimoto Y. Cancer Res; 1989 Oct 15; 49(20):5537-42. PubMed ID: 2790778 [Abstract] [Full Text] [Related]
7. Biochemical characterization of cisplatin-resistance in MKN-45 human stomach adenocarcinoma cell line. Hong WS, Son YS. Anticancer Res; 1996 Oct 15; 16(5A):3031-6. PubMed ID: 8917423 [Abstract] [Full Text] [Related]
8. Antitumor activity of (2''R)-4'-O-tetrahydropyranyl adriamycin on human gastric cancer cell lines in vitro and in vivo. Saikawa Y, Kubota T, Kuo TH, Furukawa T, Kase S, Tanino H, Ishibiki K, Kitajima M, Hoffman RM. Anticancer Res; 1994 Oct 15; 14(2A):469-73. PubMed ID: 8017850 [Abstract] [Full Text] [Related]
9. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II). Kim DK, Kim HT, Cho YB, Kim TS, Kim KH, Hong WS. Anticancer Res; 1996 Oct 15; 16(1):251-6. PubMed ID: 8615617 [Abstract] [Full Text] [Related]
10. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells. Watanabe M, Komeshima N, Naito M, Isoe T, Otake N, Tsuruo T. Cancer Res; 1991 Jan 01; 51(1):157-61. PubMed ID: 1988080 [Abstract] [Full Text] [Related]
11. An adriamycin-resistant subline is more sensitive than the parent human small cell lung cancer cell line to lonidamine. Kiura K, Ohnoshi T, Ueoka H, Takigawa N, Tabata M, Segawa Y, Shibayama T, Kimura I. Anticancer Drug Des; 1992 Dec 01; 7(6):463-70. PubMed ID: 1337430 [Abstract] [Full Text] [Related]
12. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines. Dong J, Naito M, Tatsuta T, Seimiya H, Johdo O, Tsuruo T. Oncol Res; 1995 Dec 01; 7(5):245-52. PubMed ID: 8534930 [Abstract] [Full Text] [Related]
13. In vitro antitumor activity of a new platinum complex, cis-malonato [(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum (II) (SKI 2053R), against human lung and stomach cancer cell lines. Hong WS, Kim HT, Kim KH, Kim DK. Anticancer Res; 1995 Dec 01; 15(1):51-4. PubMed ID: 7733640 [Abstract] [Full Text] [Related]
14. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line. Son YS, Suh JM, Ahn SH, Kim JC, Yi JY, Hur KC, Hong WS, Muller MT, Chung IK. Cancer Chemother Pharmacol; 1998 Dec 01; 41(5):353-60. PubMed ID: 9523730 [Abstract] [Full Text] [Related]
15. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines. Nakanishi O, Baba M, Saito A, Yamashita T, Sato W, Abe H, Fukazawa N, Suzuki T, Sato S, Naito M, Tsuruo T. Oncol Res; 1997 Dec 01; 9(2):61-9. PubMed ID: 9167187 [Abstract] [Full Text] [Related]
16. Modulation of multidrug resistance by andrographolid in a HCT-8/5-FU multidrug-resistant colorectal cancer cell line. Han Y, Bu LM, Ji X, Liu CY, Wang ZH. Chin J Dig Dis; 2005 Dec 01; 6(2):82-6. PubMed ID: 15904426 [Abstract] [Full Text] [Related]
17. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells. Watanabe M, Komeshima N, Nakajima S, Tsuruo T. Cancer Res; 1988 Dec 01; 48(23):6653-7. PubMed ID: 3180075 [Abstract] [Full Text] [Related]
18. Antitumor activity of a novel ginseng saponin metabolite in human pulmonary adenocarcinoma cells resistant to cisplatin. Lee SJ, Sung JH, Lee SJ, Moon CK, Lee BH. Cancer Lett; 1999 Sep 20; 144(1):39-43. PubMed ID: 10503876 [Abstract] [Full Text] [Related]
19. Cellular uptake and antitumor activity of the new anthracycline analog DA-125 in human cancer cell lines. Lim KH, Kim HS, Yang YM, Lee SD, Kim WB, Yang J, Park JG. Cancer Chemother Pharmacol; 1997 Sep 20; 40(1):23-30. PubMed ID: 9137525 [Abstract] [Full Text] [Related]
20. [Establishment of adriamycin-resistant human small-cell lung cancer cells in culture: analysis of the mechanism of resistance and cross-resistance]. Kimura I, Ohnoshi T, Hiraki S, Miyamoto H. Gan To Kagaku Ryoho; 1987 Mar 20; 14(3 Pt 2):830-6. PubMed ID: 3032107 [Abstract] [Full Text] [Related] Page: [Next] [New Search]